Needle-Free light therapy shows promise for common skin cancer
NCT ID NCT04552990
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new way to treat basal cell carcinoma, a common skin cancer. Instead of surgery, doctors used a jet-injection device to deliver a drug called ALA into the tumor, then activated it with red light. The trial included 16 adults with small, low-risk BCCs and aimed to see if the treatment was safe and caused only mild side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aminolevulinic acid (ALA)
What this could lead to
If successful, this could offer a less invasive treatment option for certain basal cell carcinomas, potentially reducing the need for surgery.
What could go wrong
This is a very small, early-phase trial with only 16 participants, focused on safety. It is not designed to prove effectiveness, and the approach may not work for all types of BCC or may cause skin reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States